Clinical Research Directory

FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases

Sponsor: Assistance Publique - Hôpitaux de Paris

Summary

SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.

Official title: Multicenter Cohort Study of Mid/Lower Rectal Cancer With Resectable Synchronous Liver Metastases Treated With FOLFIRINOX Induction Chemotherapy

Key Details

Conditions

Locations (1)